Literature DB >> 35275240

Diabetes, GDF-15 and incident heart failure: the atherosclerosis risk in communities study.

Justin B Echouffo-Tcheugui1, Natalie Daya2, Chiadi E Ndumele3, Kunihiro Matsushita2,3, Ron C Hoogeveen4, Christie M Ballantyne4, Josef Coresh2, Amil M Shah5, Elizabeth Selvin2.   

Abstract

AIMS/HYPOTHESIS: Elevated circulating growth differentiation factor-15 (GDF-15), a marker of cellular stress, is associated with both heart failure (HF) and diabetes. However, it is unclear to what extent GDF-15 is associated with HF among individuals with and without diabetes.
METHODS: We evaluated 10,570 participants free of HF at Visit 3 (1993-1995) of the Atherosclerosis Risk in Communities study. We used Cox regression to evaluate the joint associations of GDF-15 and diabetes with incident HF. Models were adjusted for traditional cardiovascular risk factors.
RESULTS: Among a total of 10,570 individuals (mean age of 60.0 years, 54% women, 27% black adults), elevated GDF-15 (≥75th percentile) was more common in people with diabetes compared with those without diabetes (32.8% vs 23.6%, p<0.0001). During 23 years of follow-up, there were 2429 incident HF events. GDF-15 (in quartiles) was independently associated with HF among those with and without diabetes, with a stronger association among individuals with diabetes (p-for-diabetes-GDF-15 interaction = 0.034): HR for highest vs lowest GDF-15 quartile (reference): 1.64 (95% CI 1.41, 1.91) among those without diabetes and 1.72 (95% CI 1.32, 2.23) among those with diabetes. Individuals with diabetes and elevated GDF-15 had the highest risk of incident HF (HR 2.46; 95% CI 1.99, 3.03). After accounting for HF risk factors, GDF-15 provided additional prognostic information among participants with diabetes (ΔC statistic for model with vs model without GDF-15: +0.008, p = 0.001) and among those without diabetes (+0.006, p<0.0001). CONCLUSIONS/
INTERPRETATION: In a community-based sample of US adults, GDF-15 provided complementary prognostic information on the HF risk, especially among individuals with diabetes.
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  Growth differentiation factor-15; Heart failure; Prediction; Type 2 diabetes

Mesh:

Substances:

Year:  2022        PMID: 35275240      PMCID: PMC9081127          DOI: 10.1007/s00125-022-05678-6

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.460


  44 in total

1.  MIC-1, a novel macrophage inhibitory cytokine, is a divergent member of the TGF-beta superfamily.

Authors:  M R Bootcov; A R Bauskin; S M Valenzuela; A G Moore; M Bansal; X Y He; H P Zhang; M Donnellan; S Mahler; K Pryor; B J Walsh; R C Nicholson; W D Fairlie; S B Por; J M Robbins; S N Breit
Journal:  Proc Natl Acad Sci U S A       Date:  1997-10-14       Impact factor: 11.205

2.  Development and Validation of a Protein-Based Risk Score for Cardiovascular Outcomes Among Patients With Stable Coronary Heart Disease.

Authors:  Peter Ganz; Bettina Heidecker; Kristian Hveem; Christian Jonasson; Shintaro Kato; Mark R Segal; David G Sterling; Stephen A Williams
Journal:  JAMA       Date:  2016-06-21       Impact factor: 56.272

3.  The population burden of heart failure attributable to modifiable risk factors: the ARIC (Atherosclerosis Risk in Communities) study.

Authors:  Christy L Avery; Laura R Loehr; Christopher Baggett; Patricia P Chang; Anna M Kucharska-Newton; Kunihiro Matsushita; Wayne D Rosamond; Gerardo Heiss
Journal:  J Am Coll Cardiol       Date:  2012-09-26       Impact factor: 24.094

4.  Involvement of growth differentiation factor-15/macrophage inhibitory cytokine-1 (GDF-15/MIC-1) in oxLDL-induced apoptosis of human macrophages in vitro and in arteriosclerotic lesions.

Authors:  Daniel Schlittenhardt; Andreas Schober; Jens Strelau; Gabriel A Bonaterra; Walther Schmiedt; Klaus Unsicker; Jürgen Metz; Ralf Kinscherf
Journal:  Cell Tissue Res       Date:  2004-10-01       Impact factor: 5.249

5.  Growth differentiation factor 15 (GDF-15) in patients admitted for acute heart failure: results from the RELAX-AHF study.

Authors:  Gad Cotter; Adriaan A Voors; Margaret F Prescott; G Michael Felker; Gerasimos Filippatos; Barry H Greenberg; Peter S Pang; Piotr Ponikowski; Olga Milo; Tsushung A Hua; Min Qian; Thomas M Severin; John R Teerlink; Marco Metra; Beth A Davison
Journal:  Eur J Heart Fail       Date:  2015-09-03       Impact factor: 15.534

6.  SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials.

Authors:  Faiez Zannad; João Pedro Ferreira; Stuart J Pocock; Stefan D Anker; Javed Butler; Gerasimos Filippatos; Martina Brueckmann; Anne Pernille Ofstad; Egon Pfarr; Waheed Jamal; Milton Packer
Journal:  Lancet       Date:  2020-08-30       Impact factor: 79.321

7.  GDF15 mediates the effects of metformin on body weight and energy balance.

Authors:  Anthony P Coll; Naveed Sattar; David B Savage; Bernard B Allan; Stephen O'Rahilly; Michael Chen; Pranali Taskar; Debra Rimmington; Satish Patel; John A Tadross; Irene Cimino; Ming Yang; Paul Welsh; Samuel Virtue; Deborah A Goldspink; Emily L Miedzybrodzka; Adam R Konopka; Raul Ruiz Esponda; Jeffrey T-J Huang; Y C Loraine Tung; Sergio Rodriguez-Cuenca; Rute A Tomaz; Heather P Harding; Audrey Melvin; Giles S H Yeo; David Preiss; Antonio Vidal-Puig; Ludovic Vallier; K Sreekumaran Nair; Nicholas J Wareham; David Ron; Fiona M Gribble; Frank Reimann
Journal:  Nature       Date:  2019-12-25       Impact factor: 49.962

8.  The Physical Activity Guidelines for Americans.

Authors:  Katrina L Piercy; Richard P Troiano; Rachel M Ballard; Susan A Carlson; Janet E Fulton; Deborah A Galuska; Stephanie M George; Richard D Olson
Journal:  JAMA       Date:  2018-11-20       Impact factor: 157.335

Review 9.  Mitochondrial dysfunction in type 2 diabetes mellitus: an organ-based analysis.

Authors:  Mark V Pinti; Garrett K Fink; Quincy A Hathaway; Andrya J Durr; Amina Kunovac; John M Hollander
Journal:  Am J Physiol Endocrinol Metab       Date:  2019-01-02       Impact factor: 4.310

10.  Assessment of Variability in the SOMAscan Assay.

Authors:  Julián Candia; Foo Cheung; Yuri Kotliarov; Giovanna Fantoni; Brian Sellers; Trevor Griesman; Jinghe Huang; Sarah Stuccio; Adriana Zingone; Bríd M Ryan; John S Tsang; Angélique Biancotto
Journal:  Sci Rep       Date:  2017-10-27       Impact factor: 4.379

View more
  2 in total

1.  Circulating growth differentiation factor 15 levels and apolipoprotein B to apolipoprotein A1 ratio in coronary artery disease patients with type 2 diabetes mellitus.

Authors:  Yufeng Mei; Zhiming Zhao; Yongnan Lyu; Yan Li
Journal:  Lipids Health Dis       Date:  2022-07-16       Impact factor: 4.315

Review 2.  Aptamers Targeting Cardiac Biomarkers as an Analytical Tool for the Diagnostics of Cardiovascular Diseases: A Review.

Authors:  Natalia Komarova; Olga Panova; Alexey Titov; Alexander Kuznetsov
Journal:  Biomedicines       Date:  2022-05-06
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.